CN114983939A - 一种丙泊酚乳状注射液及其制备方法 - Google Patents
一种丙泊酚乳状注射液及其制备方法 Download PDFInfo
- Publication number
- CN114983939A CN114983939A CN202210738452.4A CN202210738452A CN114983939A CN 114983939 A CN114983939 A CN 114983939A CN 202210738452 A CN202210738452 A CN 202210738452A CN 114983939 A CN114983939 A CN 114983939A
- Authority
- CN
- China
- Prior art keywords
- preparation
- nitrogen
- propofol
- emulsion
- water phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 229960004134 propofol Drugs 0.000 title claims abstract description 25
- 238000002347 injection Methods 0.000 title claims abstract description 18
- 239000007924 injection Substances 0.000 title claims abstract description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000003921 oil Substances 0.000 claims abstract description 21
- 235000019198 oils Nutrition 0.000 claims abstract description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 7
- 229940124274 edetate disodium Drugs 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 7
- 239000003549 soybean oil Substances 0.000 claims abstract description 7
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 3
- 239000012071 phase Substances 0.000 claims description 38
- 238000010008 shearing Methods 0.000 claims description 9
- 238000004945 emulsification Methods 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 3
- 230000001804 emulsifying effect Effects 0.000 abstract 1
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000002693 spinal anesthesia Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种丙泊酚乳状注射液及其制备方法。该方法具体步骤为：先使用甘油、依地酸二钠、注射用水配制水相，用1mol/L氢氧化钠溶液调节药液pH值至9.8‑10.8；用大豆油、蛋黄卵磷脂、丙泊酚配制油相；最后油相和水相混合乳化、均质。本发明通过控制配制系统的充氮置换操作和初乳液形成时水相和油相混合的流量控制制备得到乳粒均一，稳定性更好的丙泊酚乳状注射液，经长期试验乳粒变化不明显，符合质量标准的要求。
Description
技术领域
本发明属于药物制备技术领域，具体来说，涉及到一种丙泊酚乳状注射液及其制备方法。
背景技术
丙泊酚(即2，6－二异丙基苯酚)是目前临床上广泛使用的全身麻醉诱导剂和维持剂。其化学结构式：
分子式为C12H18O，分子量是178.27。丙泊酚作用于γ-氨基丁酸受体的A亚型(γ-aminobutyric acid type A，GABA-A)，以快速起效和停药后快速恢复为特征，是一种短效静脉麻醉药，用于全身麻醉的诱导和维持。常与硬膜外或脊髓麻醉同时应用，也常与镇痛药、肌松药及吸入性麻醉药同用。
现有技术中的丙泊酚乳状注射液存在长期放置过程中粒径变化，易氧化的情况，影响了丙泊酚脂肪乳剂的稳定性和安全性。
发明内容
本发明目的是提供一种丙泊酚乳状注射液及其制备方法。本发明通过控制配制系统的充氮置换操作和初乳液形成时水相和油相混合的流量控制制备得到乳粒均一，稳定性更好的丙泊酚乳状注射液。
所述的丙泊酚乳状注射液的制备方法为：
(1)水相的制备：水相配制系统先进行充氮置换操作，在氮气保护下，加入注射用水，再加入甘油、依地酸二钠，搅拌5min使混合均匀，用1mol/L氢氧化钠溶液调节药液pH值至9.8-10.8，65-80℃保温备用；
(2)油相的制备：油相配制系统先进行充氮置换操作，在氮气保护下，加入大豆油后升温至60-80℃，再加入蛋黄卵磷脂，设置剪切机转速为10000rpm，加入丙泊酚继续剪切使药液澄清，60-80℃保温备用；
(3)初乳液的制备：设置剪切机转速为10000rpm，在持续充氮保护下将油相和水相混合；
(4)精乳液的制备：初乳液进入均质机，120bar低压均质1次，然后600bar高压均质6-7次。
(5)最后灌封，灭菌。
所述丙泊酚乳状注射液的各组分用量为：丙泊酚0.2kg，大豆油2.0kg，蛋黄卵磷脂0.2kg，甘油0.5kg，依地酸二钠0.001kg，水相中注射用水的用量使水相体积为20L。
所述充氮置换操作为：充氮抽真空重复置换3-5次，每次抽真空保持负压不高于-0.6bar，保压不少于60s，每次充氮保持罐内氮气正压不低于0.5bar，保压60s。
所述油相和水相混合时油相流速为20-30kg/min，水相流速为80-70kg/min，油相、水相经乳化泵混合打入配药罐中，初乳液经乳化泵在初乳罐、配药罐之间循环乳化4-5次。
本发明所制备的丙泊酚乳状注射液乳粒均一，稳定性高，实用性强，经长期试验乳粒变化不明显，符合质量标准的要求。
具体实施方式
为了更好地了解和实施本发明，将本发明具体实施例表述一下，需要说明的是下面描述的实施例是示例性的，仅用于解释本发明，而不能理解为对本发明的限制。
实施例1
处方：
制备工艺：
(1)称量：按处方量称取甘油、依地酸二钠、大豆油、蛋黄卵磷脂、丙泊酚。
(2)水相的制备：水相配制系统先进行充氮置换操作，在氮气保护下，水相中加入注射用水，再加入处方量的甘油、依地酸二钠搅拌5min使混合均匀，用1mol/L氢氧化钠溶液调节药液pH值至10.0，药液共20L，70℃保温备用；
(3)油相的制备：油相配制系统先进行充氮置换操作，在氮气保护下，加入处方量的大豆油升温至80℃，加入蛋黄卵磷脂，设置剪切机转速为10000rpm，加入处方量的丙泊酚继续剪切使澄清，70℃保温备用；
(4)初乳液的制备：设置剪切机转速为10000rpm，在持续充氮保护下将油相和水相混合；混合时间5min；油相流速为20-30kg/min，水相流速为80-70kg/min，油相、水相经乳化泵混合打入配药罐中，初乳液经乳化泵在初乳罐、配药罐之间循环乳化5次。
(5)精乳液的制备：初乳液进入均质机，120bar低压均质1次，然后600bar高压均质6次。
(6)灌封，灭菌30分钟。
(7)灯检、包装，得成品。
步骤(2)和(3)的充氮置换操作为：充氮抽真空重复置换3次，每次抽真空保持负压不高于-0.6bar，保压60s，每次充氮保持罐内氮气正压不低于0.5bar，保压60s。
对上述制备的丙泊酚乳状注射液进行稳定性考察：置于40℃±2℃、RH75％±5％恒温恒湿箱中，分别于0、1、2、3、6月取样，检测含量、pH、有关物质，结果如下表所示：
表1加速试验考察结果
以上结果表明：按照实施例1制得的成品在40℃±2℃、RH75％±5％的条件下，经过加速6个月的考察，稳定性较其他对比产品显著提高。
Claims (4)
1.一种丙泊酚乳状注射液的制备方法，其特征在于，所述制备方法的具体步骤为：
(1)水相的制备：水相配制系统先进行充氮置换操作，在氮气保护下，加入注射用水，再加入甘油、依地酸二钠，搅拌5min使混合均匀，用1mol/L氢氧化钠溶液调节药液pH值至9.8-10.8，65-80℃保温备用；
(2)油相的制备：油相配制系统先进行充氮置换操作，在氮气保护下，加入大豆油后升温至60-80℃，再加入蛋黄卵磷脂，设置剪切机转速为10000rpm，加入丙泊酚继续剪切使药液澄清，60-80℃保温备用；
(3)初乳液的制备：设置剪切机转速为10000rpm，在持续充氮保护下将油相和水相混合；
(4)精乳液的制备：初乳液进入均质机，120bar低压均质1次，然后600bar高压均质6-7次；
(5)最后灌封，灭菌。
2.根据权利要求1所述的制备方法，其特征在于，所述丙泊酚乳状注射液的各组分用量为：丙泊酚0.2kg，大豆油2.0kg，蛋黄卵磷脂0.2kg，甘油0.5kg，依地酸二钠0.001kg，水相中注射用水的用量使水相体积为20L。
3.根据权利要求1所述的制备方法，其特征在于，所述充氮置换操作为：充氮抽真空重复置换3-5次，每次抽真空保持负压不高于-0.6bar，保压不少于60s，每次充氮保持罐内氮气正压不低于0.5bar，保压60s。
4.根据权利要求1所述的制备方法，其特征在于，所述油相和水相混合时油相流速为20-30kg/min，水相流速为80-70kg/min，油相、水相经乳化泵混合打入配药罐中，初乳液经乳化泵在初乳罐、配药罐之间循环乳化4-5次。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210738452.4A CN114983939A (zh) | 2022-06-27 | 2022-06-27 | 一种丙泊酚乳状注射液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210738452.4A CN114983939A (zh) | 2022-06-27 | 2022-06-27 | 一种丙泊酚乳状注射液及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114983939A true CN114983939A (zh) | 2022-09-02 |
Family
ID=83037317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210738452.4A Pending CN114983939A (zh) | 2022-06-27 | 2022-06-27 | 一种丙泊酚乳状注射液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114983939A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977825A (zh) * | 1995-03-17 | 2007-06-13 | 曾尼卡有限公司 | 无菌医药组合物 |
| CN102188374A (zh) * | 2010-12-29 | 2011-09-21 | 山东鲁抗辰欣药业有限公司 | 一种中长链脂肪乳注射液及其制备方法 |
| CN102366404A (zh) * | 2011-10-20 | 2012-03-07 | 四川百利药业有限责任公司 | 一种丙泊酚中/长链脂肪乳剂 |
| CN209752867U (zh) * | 2018-10-11 | 2019-12-10 | 本溪恒康制药有限公司 | 制备脂微球的设备 |
-
2022
- 2022-06-27 CN CN202210738452.4A patent/CN114983939A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977825A (zh) * | 1995-03-17 | 2007-06-13 | 曾尼卡有限公司 | 无菌医药组合物 |
| CN102188374A (zh) * | 2010-12-29 | 2011-09-21 | 山东鲁抗辰欣药业有限公司 | 一种中长链脂肪乳注射液及其制备方法 |
| CN102366404A (zh) * | 2011-10-20 | 2012-03-07 | 四川百利药业有限责任公司 | 一种丙泊酚中/长链脂肪乳剂 |
| CN209752867U (zh) * | 2018-10-11 | 2019-12-10 | 本溪恒康制药有限公司 | 制备脂微球的设备 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109692154B (zh) | 一种丙泊酚中/长链脂肪乳注射液的制备方法 | |
| DE102009056884B4 (de) | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben | |
| CN102805728A (zh) | 一种丙泊酚脂肪乳注射液及其制备方法 | |
| CN114983939A (zh) | 一种丙泊酚乳状注射液及其制备方法 | |
| CN112641821A (zh) | 一种脂肪乳注射液的配方及其制备方法 | |
| CN103961314A (zh) | 一种稳定的麻醉乳剂 | |
| CN117752608A (zh) | 一种中长链脂肪乳注射液的制备方法 | |
| CN205570128U (zh) | 一种配制搅拌系统 | |
| CN106137963B (zh) | 抗心律失常药物脂肪乳注射液及其制备方法 | |
| CN113712917A (zh) | 一种丙泊酚中长链脂肪乳注射液及其制备方法 | |
| CN112168778A (zh) | 一种丁酸氯维地平注射用乳剂及其生产方法 | |
| CN115501180A (zh) | 一种甲氨蝶呤脂肪乳注射剂及其制备方法 | |
| CN116966142A (zh) | 一种制备氟比洛芬酯注射液的方法及其应用 | |
| CN105878182A (zh) | 一种丁酸氯维地平注射用脂肪乳的制备方法 | |
| CN112402377A (zh) | 一种丙泊酚静脉注射脂肪乳剂及其制备方法 | |
| CN113197853B (zh) | 一种丁酸氯维地平注射用乳剂、其制备方法及应用 | |
| JPS60262827A (ja) | シリコ−ンエマルジヨン | |
| CN117064849A (zh) | 一种维生素k1注射液及其制备方法 | |
| WO2024012361A1 (zh) | 阿法沙龙脂肪乳注射液及其制备方法 | |
| CN109261088B (zh) | 制备脂微球的设备及制备方法 | |
| CN114949940B (zh) | 一种油田用消泡剂及其制备方法 | |
| CN101480380A (zh) | 静脉注射用的全身麻醉药及制备方法 | |
| CN114983941A (zh) | 脂肪乳注射液均匀化制备方法 | |
| CN117752596A (zh) | 一种阿瑞匹坦混合胶束注射液及其制备方法和应用 | |
| CN117379372A (zh) | 阿法沙龙脂肪乳注射液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |